TY - GEN T1 - 345 Treatment with amlitelimab鈥攁 novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody鈥攔educes IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis PY - 2023/01/25 AU - Weidinger S AU - Cork M AU - Reich A AU - Bieber T AU - Gilbert S AU - Brennan N AU - Wilson R AU - Lucchesi D AU - Rynkiewicz N AU - Stebegg M AU - Porter-Brown B ED - Y2 - 2025/05/19 ER -